Physician profile
Lisa Fields
NPI 1215333075
$3,280.72
in general payments reported to CMS, 2019-2025
17 companies · $1,253 in 2025
The $1,253 reported for 2025 was more than what 85% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $89.36 · 2023: $288 · 2024: $1,650 · 2025: $1,253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,191.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $771.81 | 2023-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $439.71 | 2024-2025 | Qelbree |
| Organogenesis INC. | $359.44 | 2022-2023 | Puraply |
| Otsuka America Pharmaceutical, INC. | $275.44 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $266.56 | 2024-2025 | Invega Sustenna, Invega Trinza |
| Axsome Therapeutics, INC. | $237.55 | 2024-2025 | Auvelity |
| Corium, LLC | $232.81 | 2024-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $172.50 | 2024 | |
| Lundbeck LLC | $123.85 | 2024-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $100.29 | 2024-2025 | Trintellix |
| Collegium Pharmaceutical, INC. | $88.67 | 2025 | Jornay Pm |
| Abbvie INC. | $79.31 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $67.95 | 2024 | Austedo Xr |
| Atricure, INC. | $22.38 | 2024 | |
| Alkermes, INC. | $15.00 | 2024 | Aristada, Lybalvi |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $13.93 | 2024 | Xelstrym, Secuado |
| Idorsia Pharmaceuticals US INC | $13.52 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Fields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.